Abeona Therapeutics (NASDAQ:ABEO) Director Eric Crombez Sells 16,284 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Eric Crombez sold 16,284 shares of Abeona Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $82,885.56. Following the completion of the transaction, the director owned 63,456 shares in the company, valued at approximately $322,991.04. This represents a 20.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Abeona Therapeutics Trading Up 1.6%

ABEO stock traded up $0.08 during trading on Monday, hitting $5.17. 756,510 shares of the company traded hands, compared to its average volume of 1,266,662. The company has a 50-day moving average of $5.15 and a 200-day moving average of $5.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a market capitalization of $280.17 million, a PE ratio of 4.20 and a beta of 1.12.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on ABEO shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ABEO. Ameritas Investment Partners Inc. purchased a new stake in shares of Abeona Therapeutics during the second quarter valued at approximately $25,000. Legal & General Group Plc bought a new position in Abeona Therapeutics in the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at $37,000. Legato Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth $57,000. Finally, SG Americas Securities LLC purchased a new position in shares of Abeona Therapeutics in the fourth quarter worth $57,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.